Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed Oct 27, 2022 · 10-Q · 27 days after period end · 0001178670-22-000026
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $264.31M | $187.63M | $125.85M | $70.06M |
| Net Income | -$405.92M | -$204.51M | -$253.29M | -$208.54M |
| EPS Diluted | -$3.32 | -$1.72 | -$2.18 | -$1.92 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Oct 27, 2022 · 27 d after period end
